Teva Fights Selection of Austedo, Xtandi in US Drug Price Cuts

Teva Pharmaceuticals Inc. is doubling down on its fight against the Medicare agency after its drugs and other medicines it competes with were selected for drug price negotiations.

The company filed an amended complaint Tuesday in the US District Court for the District of Columbia, challenging how the Centers for Medicare & Medicaid Services picked its drugs used to treat movement disorders—Austedo and Austedo XR—for the second cycle of the Medicare Drug Price Negotiation Program.

The plan created under the 2022 Inflation Reduction Act allows the US government to slash the cost of some of the most expensive and widely ...